Uploaded November 2026 | Updated November 2026, 5 days ago
A cancer detection technology developed at the Broad Institute now powers a next-generation test for molecular residual disease (MRD) launched this week by Abbott. The personalized Oncodetect® test looks for MRD — traces of cancer DNA that may remain in the body during and after treatment. It’s the result of years of collaborative work from Broad and Abbott scientists and partners from research hospitals.
A cancer detection technology developed at the Broad Institute now powers a next-generation test for molecular residual disease (MRD) launched this week by Abbott. The personalized Oncodetect® test looks for MRD — traces of cancer DNA that may remain in the body during and after treatment. It’s the result of years of collaborative work from Broad and Abbott scientists and partners from research hospitals.










